menu
    • menu
    [{"orgOrder":0,"company":"Island Pharmaceuticals","sponsor":"Beyond Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Undisclosed","graph2":"Phase I","graph3":"Island Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Island Pharmaceuticals \/ Beyond Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"Island Pharmaceuticals \/ Beyond Drug Development"}]

    Find Undisclosed Clinical Drug Pipeline Developments & Deals by Island Pharmaceuticals

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Island Pharmaceuticals

                            Australia arrow
                            Peptide Process CMC
                            Not Confirmed

                            Island Pharmaceuticals

                            Australia arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Beyond Drug Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 26, 2023

                            Lead Product(s) : Fenretinide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Beyond Drug Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth